• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Onyx Pharmaceuticals

Onyx Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer

    Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer

  2. Avion Pharmaceuticals, LLC, signs Captisol® License Agreement with Ligand Pharmaceuticals to develop four new products

    Avion Pharmaceuticals, LLC, signs Captisol® License Agreement with Ligand Pharmaceuticals to develop four new products

  3. Bayer Receives EU Approval for Stivarga for Tumor Treatment

    Bayer Receives EU Approval for Stivarga for Tumor Treatment

  4. Amgen reports successful late-stage trial of cancer treatment

    Amgen reports successful late-stage trial of cancer treatment

  5. Bayer and Onyx Say Phase III Trial of Nexavar Breast Cancer Treatment Failed

    Bayer and Onyx Say Phase III Trial of Nexavar Breast Cancer Treatment Failed

  6. Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37

    Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37

  7. Our Outlook for the Credit Markets

    Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.

  8. ClearBridge Fund Prepared for Extended Rally

    The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.